Android app on Google Play

Amarin (AMRN) Dips Following FDA Orange Book Update

January 18, 2013 2:35 PM EST Send to a Friend
Amarin Corp Plc (NASDAQ: AMRN) shares are pressured following an update to the FDA's Orange Book.

The Book had Amarin's Vascepa with "no unexpired exclusivity for this product," though no NCE decision was made.

Shares are down 7.5 percent Friday afternoon.




You May Also Be Interested In


Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment